Zonampanel
Alternative Names: YM-872Latest Information Update: 10 Sep 2015
Price :
$50 *
At a glance
- Originator Astellas Pharma
- Class Anti-ischaemics; Neuroprotectants
- Mechanism of Action AMPA receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Brain injuries; Pain; Stroke
Most Recent Events
- 11 Apr 2005 Yamanouchi has merged with Fujisawa to form Astellas Pharma
- 20 Oct 2003 This compound is still in active development
- 16 Jul 2003 Preclinical studies have been added to the adverse events Neurological disorders pharmacodynamics section